Breast Cancer | Oncology Today with Dr Neil Love: Newly Approved Agents in HER2-Positive Metastatic Breast Cancer

published 4 months ago by Dr Neil Love

Featuring an interview with Dr Mark D Pegram on the following topics: Newly approved agents in HER2-positive metastatic breast cancer (mBC) (0:00) Clinical data with neratinib for patients with mBC and HER2 mutations (22:31) Optimal integration of margetuximab into the treatment algorithm for patients with HER2-positive mBC (26:31) Case: A woman in her late 50s receives multiple lines of HER2-directed therapies for HER2-positive mBC (29:30) Mechanism of action of a novel antibody-based construct linking trastuzumab and toll-like receptors (36:49) Case: A woman in her early 70s receives trastuzumab deruxtecan for HER2-positive mBC (40:48) Monitoring for and management of interstitial lung disease associated with trastuzumab deruxtecan (44:21) Efficacy of trastuzumab deruxtecan, tucatinib and T-DM1 in patients with HER2-positive mBC (47:45) Case: A woman in her mid-50s receives tucatinib/trastuzumab/capecitabine for HER2-positive breast cancer with metastases in the brain (56:10) Management of side effects of tucatinib/capecitabine/trastuzumab for HER2-positive mBC (1:02:36) Potential role of margetuximab in the treatment of HER2-positive breast cancer (1:05:53) CME information and select publications

more episodes from Research To Practice | Oncology Videos